Our findings indicate that methylation of EMILIN2, CIDE-A and FBLN2 are associated with positive estrogen and or progesterone receptor status, this may help in further refining breast cancers that are more likely to benefit from endocrine therapy. The gene discussed is EMILIN2; the disease is breast cancer.